Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 34Prostatic Neoplasms 32Neoplasms 28Multiple Myeloma 26Pancreatic Neoplasms 24Brain Neoplasms 23Colorectal Neoplasms 19Recurrence 18Squamous Cell Carcinoma of Head and Neck 16Melanoma 16Lymphoma 15Lung Neoplasms 15Neoplasm Metastasis 14Sarcoma 13Lymphoma, B-Cell 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Leukemia, Myeloid, Acute 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Skin Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 8Lymphoma, Non-Hodgkin 8Colonic Neoplasms 8

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × mCRPC × 1 year × Clear all
NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡